Literature DB >> 19341758

Basic and clinical aspects of BOTOX.

Mitchell F Brin1.   

Abstract

BOTOX is a botulinum toxin type A product from Allergan that is approved in more than 70 countries, where it addresses unmet patient needs across a variety of indications. BOTOX is a well-characterized and highly purified biological product that is not interchangeable with any other botulinum neurotoxin. The pharmacology, efficacy and safety profile of BOTOX has been established in numerous preclinical and clinical studies in addition to meta-analyses. BOTOX exhibits a predictable response, with a concomitant low rate of neutralizing antibody formation. Allergan is committed to the development of new indications and novel biologics that are designed to benefit individuals with unmet medical needs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19341758     DOI: 10.1016/j.toxicon.2009.03.021

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  6 in total

Review 1.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

2.  Ultrastructural evaluation of intramuscular applied botulinum toxin type A in striated muscles of rats.

Authors:  H Kocaelli; M Yaltirik; M Ayhan; F Aktar; B Atalay; S Yalcin
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

3.  Efficacy of botulinum toxin type a for treating chronic low back pain.

Authors:  Seyed M Jazayeri; Alireza Ashraf; Habib M Fini; Hajar Karimian; Mohamadreza V Nasab
Journal:  Anesth Pain Med       Date:  2011-09-26

Review 4.  Antiviral lectins: Selective inhibitors of viral entry.

Authors:  Carter A Mitchell; Koreen Ramessar; Barry R O'Keefe
Journal:  Antiviral Res       Date:  2017-03-18       Impact factor: 5.970

5.  Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay.

Authors:  Nicholas G James; Shiazah Malik; Bethany J Sanstrum; Catherine Rhéaume; Ron S Broide; David M Jameson; Amy Brideau-Andersen; Birgitte S Jacky
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

6.  Botulinum Neurotoxins (BoNTs)-Antibody and Vaccine.

Authors:  Jianlong Lou; James D Marks
Journal:  Toxins (Basel)       Date:  2018-11-26       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.